{
    "symbol": "ACB",
    "quarter": 3,
    "year": 2022,
    "date": "2022-05-12 21:22:12",
    "content": " While growth in patient numbers is moderated due to slow prescriber adoption, Germany remains the largest market in the EU, and 83 million citizens and we're bullish, given the new coalition's plans to legalize adult rec cannabis and improve medical patient accessibility. So, pulling all of this together, yes, we generated an adjusted EBITDA loss in Q3 2022 of $12.3 million, $3.2 million change in adjusted EBITDA loss as compared to last quarter was primarily driven by the lower level of sales in the Israel, and was partially offset with a $2.3 million decrease in adjusted SG&A expense."
}